Literature DB >> 15005240

Persistent use of false myeloma cell lines.

Hans G Drexler1, Yoshinobu Matsuo, Roderick A E MacLeod.   

Abstract

Multiple myeloma (MM) is a neoplasm of a terminally differentiated B-cell. Human myeloma cell lines were shown to be suitable model systems for use in various fields of the biological sciences. Within the last 20 years more than 100 cell lines have been established. So-called 'myeloma cell lines' have been previously reported and are still widely used which are in reality Epstein-Barr virus (EBV)-positive B-lymphoblastoid cell lines. The presence of the EBV-genome in residual normal B-cells provides them with a selective growth advantage after explantation. Cell lines represent an extremely important resource for research in a variety of fields and disciplines. As the cell lines are used as in vitro model systems in lieu of primary material, it is crucial that the cells in the culture flasks faithfully correspond to the purported objects of study. On closer examination, the use of false cell lines may be seen to invalidate a significant percentage of scientific work, or at least cast doubts on the relevance of these in vitro results to the cell type or tumor in vivo. Ultimately, use of cross-contaminated cell lines is a waste of human and material resources. Henceforth, it should be mandatory to prove the proper derivation of each new cell line by comparing DNA fingerprints or karyotypes of the patient's primary cells and the cultured cells. The availability of well characterized and authenticated bona fide MM cell lines is of great importance for the study of the biology, etiology and treatment of the disease.

Entities:  

Mesh:

Year:  2003        PMID: 15005240     DOI: 10.1111/j.1749-0774.2003.tb00140.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  15 in total

1.  Cell contamination leads to inaccurate data: we must take action now.

Authors:  G N Stacey
Journal:  Nature       Date:  2000-01-27       Impact factor: 49.962

2.  Persistent use of misidentified cell lines and its prevention.

Authors:  Roderick A F MacLeod; Willy G Dirks; Hans G Drexler
Journal:  Genes Chromosomes Cancer       Date:  2002-01       Impact factor: 5.006

Review 3.  Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Authors:  H G Drexler; Y Matsuo
Journal:  Leuk Res       Date:  2000-08       Impact factor: 3.156

4.  Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma.

Authors:  Y Matsuoka; G E Moore; Y Yagi; D Pressman
Journal:  Proc Soc Exp Biol Med       Date:  1967 Aug-Sep

Review 5.  History and classification of human leukemia-lymphoma cell lines.

Authors:  H G Drexler; J Minowada
Journal:  Leuk Lymphoma       Date:  1998-10

6.  Widespread intraspecies cross-contamination of human tumor cell lines arising at source.

Authors:  R A MacLeod; W G Dirks; Y Matsuo; M Kaufmann; H Milch; H G Drexler
Journal:  Int J Cancer       Date:  1999-11-12       Impact factor: 7.396

7.  Survey of ATCC stocks of human cell lines for HeLa contamination.

Authors:  K S Lavappa
Journal:  In Vitro       Date:  1978-05

Review 8.  Human cancer cell lines: fact and fantasy.

Authors:  J R Masters
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

9.  False leukemia-lymphoma cell lines: an update on over 500 cell lines.

Authors:  H G Drexler; W G Dirks; Y Matsuo; R A F MacLeod
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

10.  Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts.

Authors:  Ulf Klein; Annunziata Gloghini; Gianluca Gaidano; Amy Chadburn; Ethel Cesarman; Riccardo Dalla-Favera; Antonino Carbone
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

View more
  4 in total

1.  The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.

Authors:  Jiro Kikuchi; Satoshi Yamada; Daisuke Koyama; Taeko Wada; Masaharu Nobuyoshi; Tohru Izumi; Miyuki Akutsu; Yasuhiko Kano; Yusuke Furukawa
Journal:  J Biol Chem       Date:  2013-07-22       Impact factor: 5.157

2.  Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.

Authors:  Jiro Kikuchi; Daisuke Koyama; Harumi Y Mukai; Yusuke Furukawa
Journal:  Int J Hematol       Date:  2014-04-06       Impact factor: 2.490

3.  Defective Epstein-Barr Virus Genomes and Atypical Viral Gene Expression in B-Cell Lines Derived from Multiple Myeloma Patients.

Authors:  Fang Lu; Kayla A Martin; Samantha S Soldan; Andrew V Kossenkov; Priyankara Wickramasinghe; Olga Vladimirova; Alessandra De Leo; Cindy Lin; Yulia Nefedova; Paul M Lieberman
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

4.  Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.

Authors:  Jiro Kikuchi; Naoya Shibayama; Satoshi Yamada; Taeko Wada; Masaharu Nobuyoshi; Tohru Izumi; Miyuki Akutsu; Yasuhiko Kano; Kanako Sugiyama; Mio Ohki; Sam-Yong Park; Yusuke Furukawa
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.